ArticleBMC cancer2025
A prognostic model based on immune cells in tumor microenvironment to predict prognosis in endometrial cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe interaction between the tumor immune microenvironment (TIME) and malignant tumor cells plays a crucial role in tumor initiation and progression. This study aimed to establish and validate a prognostic model based on TIME characteristics to predict prognosis and guide personalized treatment in patients with endometrial cancer (EC).
methodsA total of 67 EC patients who underwent surgery and TIME profiling at Peking University People's Hospital between January 2018 and December 2022 were included in this study. A prognostic model was developed based on the densities of stroma CD3
results(1) Multiplex immunofluorescence (mIF) analysis of the 67 EC patients revealed significant differences between the Recurrence and Non-Recurrence groups in the densities of stroma PD-L1
conclusionThis study identified two immune cell types-Stroma CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.